AI Summary
The text concludes that tenecteplase should be the first choice for thrombolytic treatment, based on its effectiveness and ease of use.
This result, along with its ease of use, adds to the growing evidence that tenecteplase should be a first-line thrombolytic agent, trial investigators say.
Medscape Medical News